Date: Feb 24, 2015 Source: Business Wire (
click here to go to the source)
BEDFORD, Mass.--(BUSINESS WIRE)--N2 Biomedical LLC today announced the receipt of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Dental & Craniofacial Research (NIDCR), to investigate a new antimicrobial biodegradable bone graft material. The project will be carried out in collaboration with Prof. Huinan Liu at the University of California at Riverside.
According to Arash Aslani, Principal Investigator, "Prevention of implant-related infections after surgical repair of traumatic craniofacial injuries is an important goal. Current materials utilized to address large bone defects, such as polymethyl methacrylate (PMMA) beads, are not ideal because they do not degrade and thus require multiple surgeries; they are also prone to infection despite the addition of antibiotics. The objective of this Phase I study is to develop a new biodegradable metallic material coupled with an innovative coating system that provides longer-term antibiotic delivery to the local environment. This technology has the potential for significantly reducing infection rates and obviating the need for a subsequent surgical procedure to remove the beads."
Mark Little, President & CEO of N2 Biomedical stated, "We are pleased with the receipt of this grant from NIH. The project has the potential for addressing an important clinical problem by improving the management of bone fractures and reducing the occurrence of infection. As a provider of coating and surface treatment services for medical devices, this technology will complement our existing commercial processes for orthopedic materials and devices. The grant will also allow us to work with and further develop technologies for the next generation of advanced biodegradable metallic materials."
About N2 Biomedical LLC
N2 Biomedical is a leading provider of surface modification services for improving the performance of medical devices. The company offers customized coatings and surface treatments to meet a variety of performance improvement needs, including reduced wear, enhanced bone in-growth, higher lubricity, antimicrobial properties, radiopacity, and electrical conductivity/insulation.
Disclaimer: The content of this news release is solely the responsibility of N2 Biomedical LLC and does not necessarily represent the official views of the National Institutes of Health.
Contacts
N2 Biomedical
Arash Aslani, 781-275-2727
Staff Scientist
aslani@n2bio.com
